Clinical Trials for Treatment: Treatment

89 Open Trials. Phone:(877.827.8839)
Protocol No. Title Status
ALLIANCE-A011502 A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial Open
ALLIANCE-A021502 Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair (ATOMIC) Open
ALLIANCE-A041501 A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL Open
ALLIANCE-A071601 Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas Open
ALLIANCE-A221505 Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction Open
ECOG-E1910 A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults Open
ECOG-E1A11 Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE) Open
ECOG-EAY131 Molecular Analysis for Therapy Choice (MATCH) Open
GOG-0263 Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy Open
GOG-0279 A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva Open
GOG-0724 Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy Open
GOG-3015 A Phase III, Multicenter, Randomized Study of Atezolizumab Versus Placebo Administered in Combination with Paclitaxel, Carboplatin, and Bevacizumab for Patients with Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Open
GOG-3016 An open-label, randomized, phase 3 clinical trial of REGN2810 versus therapy of investigator's choice chemotherapy in recurrent or metastatic platinum-refractory cervical carcinoma Open
NRG-BN003 Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma Open
NRG-BR002 A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer Open
NRG-GI004 Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer Open
NRG-HN001 Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) Open
NSABP-B-51 A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy Open
SWOG-N1048 A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision Open
SWOG-S1207 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer Open
SWOG-S1418 A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy Open
SWOG-S1609 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Open
SWOG-S1613 A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in HER2 Amplified Irinotecan-Refractory Metastatic Colorectal Cancer (mCRC) Open
UCI-01-61 A Humanitarian Device Exemption Use Protocol of TheraSphere® HUD For Treatment of Unresectable Primary or Secondary Liver Cancer Open
UCI-07-40 Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer (Appendix T) Open
UCI-14-58 Phase I, Multi-Center, Open-Label, Dose-Escalation, Combination Study of Marizomib and Bevacizumab in Bevacizumab-Naïve Subjects with WHO Grade IV Malignant Glioma Followed by Phase II Studies of Single Agent Marizomib and Combination Marizomib and Bevacizumab, and Phase I Dose-Escalation Study of Enternally-Administered Marizomib with Bevacizumab Open
UCI-14-67 A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel with Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting Open
UCI-14-95 A Phase I/II Study of the Blinatumomab in Combination with the PD-1 Inhibitor Pembrolizumab (MK-3475) for the Treatment of Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia Open
UCI-15-18 An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy Open
UCI-15-77 A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy Open
UCI-15-79 Phase II Open-Label Randomized Study of Radiosurgery with or without Tumor Treating Fields (TT Fields) for 1-10 Brain Metastases from Non-Small Cell Lung Cancer (NSCLC) Open
UCI-15-80 A Phase III Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF /Thymidine Kinase-Deactivated Virus) Followed by Sorafenib versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) without Prior Systemic Therapy Open
UCI-15-81 Phase I Dose-Escalating Study of Combining Tirapazamine and Transarterial Embolization (TAE) in Hepatocellular Carcinoma and Other Gastro-Intestinal Cancers with Liver-Only Metastasis Open
UCI-15-82 A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) Open
UCI-15-94 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma Open
UCI-16-100 A Phase II/III Multicenter, Open-label, Three-Arm, Two-Stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy Open
UCI-16-22 A Phase III, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma that Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy Open
UCI-16-40 An Open-Label Multicenter Phase I Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects with Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma Open
UCI-16-46 A Phase I dose-ranging study to investigate the safety, tolerability and pharmacokinetics of MRG-106 following local intratumoral, subcutaneous, and intravenous administration in subjects with various lymphomas and leukemias Open
UCI-16-50 A Phase Ib/II, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination with AZD9150 or AZD5069 in Patients with Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination with MEDI4736 as Second Line Treatment in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Open
UCI-16-52 A Single Arm, Open-Label, Phase IIb Study to Assess the Efficacy and Safety of the Combination of Cediranib and Olaparib Tablets in Women with Recurrent Platinum Resistant Epithelial Ovarian Cancer, Including Fallopian Tube and/or Primary Peritoneal Cancer who Do Not Carry a Deleterious or Suspected Deleterious Germline BRCA Mutation Open
UCI-16-69 ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Open
UCI-16-72 A Randomized Double-Blind Phase III Study of Avelumab in Combination with Standard of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) versus Standard of Care Chemoradiotherapy in the Front-Line Treatment of Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck Open
UCI-16-74 A Phase III Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine Open
UCI-16-76 Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365) Open
UCI-16-79 A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) Open
UCI-16-81 Prospective Randomized Trial Comparing Trans-Arterial Chemoembolization Outcome Using Cone Beam CT vs. Conventional Fluoroscopy Open
UCI-16-84 A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Of Atezolizumab (Anti-PD-L1 Antibody) As Adjuvant Therapy In Patients With Renal Cell Carcinoma At High Risk Of Developing Metastasis Following Nephrectomy Open
UCI-16-94 Phase IIA Single-Arm Study of Treatment of Patients with Advanced Liver Cancer with a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti- PD-1 Monoclonal Antibody Open
UCI-16-95 A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of a Non-Covalent, Reversible Bruton's Tyrosine Kinase Inhibitor, SNS 062, in Patients With B-Lymphoid Malignancies Open
UCI-16-96 A Phase I Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Open
UCI-17-02 A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Subjects with Metastatic Castrate Resistant Prostate Cancer (CRPC) and Relapsed/Refractory Acute Myeloid Leukemia (AML) Open
UCI-17-100 A Phase 1/2 Study of alectinib in RET-rearranged non-small cell lung cancer or RET mutated thyroid cancer Open
UCI-17-101 A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) Open
UCI-17-107 A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination with Bevacizumab Compared with Sorafenib in Patients with Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma Open
UCI-17-114 A Randomized (1:1), Double-Blind, Multi-Center, Placebo Controlled Study Evaluating Intensive Chemotherapy With or Without Glasdegib (PF-04449913) or Azacitidine (AZA) With or Without Glasdegib in Patients with Previously Untreated Acute Myeloid Leukemia Open
UCI-17-115 Phase II trial of AV-GBM-1 (autologous dendritic cells loaded with autologous tumor associated antigens) as an adjunctive therapy following primary surgery plus concurrent chemoradiation in patients with newly diagnosed glioblastoma Open
UCI-17-18 A Single-Arm, Open-Label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy Open
UCI-17-19 A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects with Relapsed or Refractory Haematologic Malignancies Open
UCI-17-28 Immediate Adjuvant Chemotherapy for Invasive Colonic Adenocarcinoma Open
UCI-17-31 An Open-Label Phase II Study of Itacitinib (INCB039110) in Combination with Low Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects with Myelofibrosis Open
UCI-17-35 A Randomized, Multicenter, Phase II Study of DSP-7888 Dosing Emulsion Combination with Bevacizumab (Bev) versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy Open
UCI-17-36 A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma Open
UCI-17-39 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation Open
UCI-17-47 A Phase Ib/II Open-Label, Dose Escalation and Expansion Study of Orally Administered VRx-3996 and Valganciclovir in Subjects with Epstein-Barr Virus-Associated Lymphoid Malignancies Open
UCI-17-48 A Multinational Phase III, Randomized, Open-label, Parallelgroup Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer (HERO) Open
UCI-17-70 A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-HodgkinÂ’s Lymphoma Open
UCI-17-81 [EXEMPTED-EXPANDED ACCESS] An expanded access protocol for lorlatinib for treatment of patients with advanced non-small cell lung cancer harboring specific molecular alterations Open
UCI-17-82 A Randomized, Double-Blind, Multi-Centre, Placebo-Controlled, Parallel-Arm Phase II Trial to Assess Safety, Efficacy and Pharmacokinetics of CD11301 0.03% and 0.06% Gel in the Treatment of Cutaneous T-Cell Lymphoma (CTCL), Stages IA, IB and IIA Open
UCI-17-83 A Phase I/II Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer Open
UCI-17-84 Multicenter Phase II Study of Transanal Total Mesorectal Excision (taTME) with Laparoscopic Assistance for Rectal Cancer Open
UCI-17-86 Phase I Trial of Efficacy and Feasibility of Robot Assisted Salvage Pelvic Lymph Node Dissection (RS-PLND) or Robot Assisted Salvage Pelvic Mass Resection (RS-PMR) Post-Robot Assisted Radical Prostatectomy Open
UCI-17-88 Open-label, Randomized, Controlled, Phase III Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects Open
UCI-17-89 A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma Open
UCI-17-90 A Two-Part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients with HER2-Positive Solid Tumors Whose Disease Progressed on Prior HER2 Targeted Therapy Open
UCI-17-92 TATE versus TACE, an Open-Label Randomized Study Comparing TransArterial Tirapazamine Embolization versus TransArterial ChemoEmbolization in Intermediate Stage Hepatocellular Carcinoma Open
UCI-17-97 A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma (HIMALAYA) Open
UCI-18-02 A Phase II, Non-Randomized, Open Label, Single Arm, Multi-Center Study of Talazoparib for Neoadjuvant Treatment of Germline BRCA1/2 Mutation Patients with Early Triple-Negative Breast Cancer Open
UCI-18-06 A phase II, multicenter, open-label, two-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment Open
UCI-18-09 A Phase 1b Study of Venetoclax and Alvocidib in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Open
UCI-18-14 A Phase I, Open-Label, Multicenter Dose Escalation Study of RMC-4630 Monotherapy in Adult Patients with Relapsed/Refractory Solid Tumors Open
UCI-18-15 A Phase III, Randomized, Double-Blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab or Placebo as First-Line Treatment in Participants with HER2 Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE 811) Open
UCI-18-17 Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) Open
UCI-18-18 A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789) Open
UCI-18-19 An Open-Label, Phase Ib Multicenter Study of IBI308 in Subjects with Advanced/Metastatic Solid Malignancies Open
UCI-18-22 A Phase I/II study of Ceritinib + Trametinib in Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Open
UCI-18-32 A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer Open
UCI-18-41 A Phase IIa Open-label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and Oxaliplatin in Subjects with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin Lymphoma Open
UCI-18-49 (Emergency Use) Single-Patient Access Treatment Using Osimertinib And Blu-667 For Advanced Non-Small Cell Lung Cancer With A Concomitant EGFR Mutation And Ret Fusion. Patient K.M. Open